Antiepileptic Drugs Market

Antiepileptic Drugs Market - Global
Industry Analysis, Size, Share, Growth
Trends and Forecast upto 2023
Transparency Market Research Reports incorporated a definite
business overview and investigation inclines on "Antiepileptic
Drugs Market". This report likewise incorporates more
illumination about fundamental review of the business including
definitions, requisitions and worldwide business sector industry
structure.
Antiepileptic drugs are therapies approved to treat patients with
epilepsy, a brain disorder in which clusters of nerve cells signal
abnormally, which can lead to seizures. These seizures are
incidents that occur when group of nerve cells or neurons in
brain sends wrong signals. Patients suffering from epilepsy may
complain about strange emotions and sensations or they may
behave strangely. Epilepsy is the fourth most common brain
disorder affecting people of all ages. The causes of epilepsy are
undetermined however major risk factors involved include brain
injury, brain tumor, stroke, and substance use disorders.
For the treatment of epilepsy, antiepileptic medicines (AEDs)
are prescribed, preference of the drug depending on the age of
the patient, type of seizures to be treated, seriousness of the
seizures, and part of the brain involved. Alcoholism, smoking,

changing lifestyle and rising geriatric population are the major
factor driving the antiepileptic market.
Browse Full Research Report on Antiepileptic Drugs
Market:
http://www.transparencymarketresearch.com/antiepileptic-drugsmarket.html
The market for antiepileptic drugs is broadly classified on the
basis of first generation antiepileptic drugs and second
generation antiepileptic drugs and pipeline drugs. First
generation antiepileptic drugs consists of Valproate (Depakote),
Oxycarbazepine ((Trileptal), Carbamazepine (Carbatrol),
Phenobarbital (Luminal), Primidone (Mysoline), Ethosuximide
(Zarontin), Topiramate (Topamax) Phenytoin (Dilantin,
Phenytek).
Second generation antiepileptic drugs consist of different
mechanism of action than the first generation drugs. These
consists of Lamotrigine (Lamictal), Pregabalin (Lyrica),
Eslicarbazepine acetate Zonisamide (Zonegran), Lacosamide
(Vimpat), Levetiracetam (Keppra), (Aptiom/Zebinix),
Perampanel (Fycompa), Rufinamide (Banzel/Inovelon),
Ezogabine/retigabine (Trobalt/Potiga),.
First generation antiepileptic drugs majorly carbamazepine,
valproate, phenytoin and oxycarbazepine are dominating the

epilepsy therapeutics market. However, second generation AEDs
such as levetiracetam, zonisamide and lacosamide are slowly
overtaking the antiepileptic drugs market due to its improved
tolerability and efficacy.
The pipeline for antiepileptic drugs has been segmented on
different phases. The drugs in the phase III of the pipeline
include Brivaracetam (UCB Pharma Ltd), Ganaxolone (Marinus
Pharmaceuticals), USL261 (Upsher Smith Laboratories, Inc.),
Perampanel (Eisai Co) and YKP3089 (SK Life Sciences) and
others. The phase I and II of the pipeline drugs include
Buspirone, Everoline, UCB0942 (PPSI), Lacosamide,
GWP42006, TAK-932 and others. All this drugs are currently
under clinical trials and it is expected that these drugs will prove
beneficial for epilepsy therapeutics market.
Geographically, North America dominates the global
antiepileptic drugs market followed by Europe majorly due to
the extensive research and development activities in the
neurology and the presence of pharmaceutical industries in the
region. Epilepsy affects approximately 2.5 million people in the
United States, and results in an estimated annual cost of
approximately $15.5 billion in healthcare. Three new
antiepileptic drugs have been approved in U.S. since 2012
including ezogabine/retigabine, perampanel and eslicarbazepine
acetate. Continuous increase in uptake of second generation

antiepileptic drugs is also driving the antiepileptic drugs market
in North America and Europe.
Asia-Pacific is also increasing constantly in the antiepileptic
drugs market mainly due to the high prevalence of epilepsy in
India and China, increased penetration due to better market
access options in China and expected approval of drugs with
novel mechanisms are some of the factors responsible for
expanding the epilepsy therapeutics market in the Asia-Pacific
region. Latin America is also a growing market for antiepileptic
drugs due to developing healthcare expenditure and high
prevalence rate of epilepsy in the region.
Some of the major players in epilepsy therapeutics market
include Abbott Laboratories, Cephalon, Inc, GlaxoSmithKline
plc,., Johnson & Johnson, Novartis AG, Pfizer, Inc., Sunovion
Pharmaceuticals, Inc., Valeant Pharmaceuticals International,
Inc., Sanofi S.A. and UCB Pharma Ltd.
About Us
Transparency Market Research (TMR) is a global market
intelligence company providing business information reports

and services. The company’s exclusive blend of quantitative
forecasting and trend analysis provides forward-looking insight
for thousands of decision makers. TMR’s experienced team of
analysts, researchers, and consultants use proprietary data
sources and various tools and techniques to gather and analyze
information.
TMR’s data repository is continuously updated and revised by a
team of research experts so that it always reflects the latest
trends and information. With extensive research and analysis
capabilities, Transparency Market Research employs rigorous
primary and secondary research techniques to develop
distinctive data sets and research material for business reports.
Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com